Risk assessment of type I gastric neuroendocrine tumors based on endoscopic and clinical features of autoimmune gastritis

Table 1 Clinical characteristics of autoimmune gastritis patients with or without gastric neuroendocrine tumors, n (%)

Variables	Total (n = 303)	Non-gNETs group (n = 187)	gNETs group (n = 116)	P value
Age, years, mean ± SD	58.2 ± 11.7	60.6 ± 11.5	54.3 ± 10.8	< 0.001b
Sex			0.421
Male	109 (36.0)	64 (34.2)	45 (38.8)
Female	194 (64.0)	123 (65.8)	71 (61.2)
Concomitant diseases
Gastric mucosal neoplasia	10 (3.3)	8 (4.3)	2 (1.7)	0.327
Tumors other than gastric mucosal neoplasia	32 (10.6)	24 (12.8)	8 (6.9)	0.102
Anemia	142 (46.9)	78 (41.7)	64 (55.2)	0.022a
Autoimmune thyroiditis	88 (40.9)	36 (34)	52 (47.7)	0.04a
Other autoimmune diseases	21 (7.0)	15 (8.1)	6 (5.2)	0.337
H. pylori				< 0.001b
Probably uninfected	240 (79.2)	131 (70.1)	109 (94)
Previously infected	44 (14.5)	40 (21.4)	4 (3.4)
Currently infected	12 (4.0)	9 (4.8)	3 (2.6)
No records	7 (2.3)	7 (3.7)	0 (0)
B12 supplement	163 (53.8)	86 (46)	77 (66.4)	0.001b
Iron supplement	77 (25.4)	43 (23)	34 (29.3)	0.22

^aP < 0.05.

^bP < 0.01.

H. pylori: Helicobacter pylori; gNETs: Gastric neuroendocrine tumors.